EP2049665A2
(en)
*
|
2006-07-28 |
2009-04-22 |
Applera Corporation |
Dinucleotide mrna cap analogs
|
WO2009058911A2
(en)
*
|
2007-10-31 |
2009-05-07 |
Applied Biosystems Inc. |
Preparation and isolation of 5' capped mrna
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
CN101671669B
(zh)
*
|
2009-08-27 |
2012-05-02 |
浙江大学 |
一种肝癌靶向性基因表达元件ae及其应用
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CA2821992A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
ES2911677T3
(es)
|
2011-10-03 |
2022-05-20 |
Modernatx Inc |
Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
|
DE12858350T1
(de)
|
2011-12-16 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte mrna zusammensetzungen
|
JP6490426B2
(ja)
|
2012-02-29 |
2019-03-27 |
サンガモ セラピューティクス, インコーポレイテッド |
ハンチントン病を治療するための方法および組成物
|
EP3501550A1
(en)
|
2012-04-02 |
2019-06-26 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
JP6491113B2
(ja)
|
2013-02-25 |
2019-03-27 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
EP3068905A4
(en)
|
2013-11-11 |
2017-07-05 |
Sangamo BioSciences, Inc. |
Methods and compositions for treating huntington's disease
|
EP3960856A1
(en)
|
2013-11-13 |
2022-03-02 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
EP3080143B1
(en)
|
2013-12-09 |
2019-02-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating hemophilia
|
AU2014375404C1
(en)
|
2013-12-30 |
2020-11-19 |
CureVac Manufacturing GmbH |
Methods for RNA analysis
|
EP3540060A1
(en)
|
2013-12-30 |
2019-09-18 |
CureVac AG |
Methods for rna analysis
|
ES2796087T3
(es)
|
2014-02-03 |
2020-11-25 |
Sangamo Therapeutics Inc |
Métodos y composiciones para el tratamiento de beta talasemia
|
WO2015143046A2
(en)
|
2014-03-18 |
2015-09-24 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
US11110154B2
(en)
|
2014-05-08 |
2021-09-07 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating Huntington's Disease
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
EP3151846A4
(en)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for nuclease design
|
WO2015188933A1
(en)
|
2014-06-10 |
2015-12-17 |
Curevac Ag |
Methods and means for enhancing rna production
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
WO2016154596A1
(en)
|
2015-03-25 |
2016-09-29 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
US20180094243A1
(en)
|
2015-04-03 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
BR112017018368B1
(pt)
|
2015-04-22 |
2022-08-02 |
Curevac Ag |
Composição contendo rna para uso no tratamento ou profilaxia de doenças tumorais e/ou cancerosas, e uso de um rna para a preparação da composição
|
CA2986310A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
AU2016262521A1
(en)
|
2015-05-11 |
2017-12-14 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating HIV infection and AIDS
|
KR20170141217A
(ko)
|
2015-05-12 |
2017-12-22 |
상가모 테라퓨틱스, 인코포레이티드 |
유전자 발현의 뉴클레아제-매개된 조절
|
EP4108769B1
(en)
|
2015-05-29 |
2023-08-30 |
CureVac Manufacturing GmbH |
A method for producing and purifying rna, comprising at least one step of tangential flow filtration
|
AU2016276702B2
(en)
|
2015-06-09 |
2022-07-28 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for improving transplantation
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
EP3317424B1
(en)
|
2015-07-01 |
2023-09-06 |
CureVac Manufacturing GmbH |
Method for analysis of an rna molecule
|
HUE055458T2
(hu)
|
2015-09-21 |
2021-11-29 |
Trilink Biotechnologies Llc |
Kompozíciók és módszerek 5'-Cap RNS-ek szintézisére
|
EA037993B1
(ru)
|
2015-09-23 |
2021-06-21 |
Сангамо Терапьютикс, Инк. |
Репрессоры htt и их применение
|
US11866754B2
(en)
|
2015-10-16 |
2024-01-09 |
Modernatx, Inc. |
Trinucleotide mRNA cap analogs
|
WO2017066781A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified phosphate linkage
|
CA3001351A1
(en)
|
2015-10-21 |
2017-04-27 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating hepatitis b virus
|
CN109312338B
(zh)
|
2015-10-30 |
2022-09-27 |
爱迪塔斯医药公司 |
治疗单纯疱疹病毒的crispr/cas相关方法及组合物
|
US10639383B2
(en)
|
2015-11-23 |
2020-05-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
SG10202005640UA
(en)
|
2015-12-18 |
2020-07-29 |
Sangamo Therapeutics Inc |
Targeted disruption of the mhc cell receptor
|
US11352631B2
(en)
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
EP3394280A1
(en)
|
2015-12-23 |
2018-10-31 |
CureVac AG |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
US20190049414A1
(en)
|
2016-02-15 |
2019-02-14 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
WO2017149139A1
(en)
|
2016-03-03 |
2017-09-08 |
Curevac Ag |
Rna analysis by total hydrolysis
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
ES2900272T3
(es)
|
2016-04-22 |
2022-03-16 |
BioNTech SE |
Métodos para proporcionar ARN monocatenario
|
WO2017191258A1
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Influenza mrna vaccines
|
US11141474B2
(en)
|
2016-05-04 |
2021-10-12 |
Curevac Ag |
Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof
|
US20180126003A1
(en)
*
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
CN116850305A
(zh)
|
2016-05-06 |
2023-10-10 |
朱诺治疗学股份有限公司 |
基因工程化细胞及其制备方法
|
EP3484870B1
(en)
|
2016-07-13 |
2022-11-16 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
EP3500295A2
(en)
|
2016-08-19 |
2019-06-26 |
CureVac AG |
Rna for cancer therapy
|
CN110325635B
(zh)
|
2016-08-24 |
2023-12-26 |
桑格摩生物治疗股份有限公司 |
使用工程化的核酸酶调控基因表达
|
SG10202007392SA
(en)
|
2016-08-24 |
2020-09-29 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
BR112019007210A2
(pt)
|
2016-10-20 |
2019-08-13 |
Sangamo Therapeutics Inc |
métodos e composições para o tratamento da doença de fabry
|
CN110352071A
(zh)
|
2016-10-26 |
2019-10-18 |
库瑞瓦格股份公司 |
脂质纳米颗粒mRNA疫苗
|
AU2017347928A1
(en)
|
2016-10-31 |
2019-05-09 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
IL266862B2
(en)
|
2016-12-01 |
2024-01-01 |
Sangamo Therapeutics Inc |
Tau modulators and methods and preparations for their administration
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
EP3558355A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Henipavirus vaccine
|
CN110662838B
(zh)
|
2017-02-22 |
2024-05-28 |
克里斯珀医疗股份公司 |
用于基因编辑的组合物和方法
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
CA3059793A1
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
KR20200024905A
(ko)
|
2017-07-04 |
2020-03-09 |
큐어백 아게 |
신규 핵산 분자
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
US20200283497A1
(en)
|
2017-09-13 |
2020-09-10 |
Biontech Cell & Gene Therapies Gmbh |
Rna replicon for expressing at cell receptor or an artificial t cell receptor
|
CA3075549A1
(en)
|
2017-09-13 |
2019-03-21 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for reprogramming somatic cells
|
WO2019053003A1
(en)
|
2017-09-13 |
2019-03-21 |
Biontech Rna Pharmaceuticals Gmbh |
METHODS FOR ENHANCING RNA EXPRESSION IN CELL
|
RU2020117848A
(ru)
|
2017-11-08 |
2021-12-08 |
Куревак Аг |
Адаптиция последовательности phk
|
AU2018364660B2
(en)
|
2017-11-09 |
2022-05-19 |
Sangamo Therapeutics, Inc. |
Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
WO2019122371A1
(en)
|
2017-12-21 |
2019-06-27 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
EP3740480B1
(en)
|
2018-01-17 |
2024-03-06 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
AU2019209292B2
(en)
|
2018-01-17 |
2023-10-05 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
WO2019143675A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
AU2019235424B2
(en)
*
|
2018-03-15 |
2023-12-21 |
BioNTech SE |
5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing RNA, expressing proteins and in therapy
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
EP4227319A1
(en)
|
2018-04-17 |
2023-08-16 |
CureVac SE |
Novel rsv rna molecules and compositions for vaccination
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
CN113015741A
(zh)
|
2018-09-18 |
2021-06-22 |
桑格摩生物治疗股份有限公司 |
程序性细胞死亡1(pd1)特异性核酸酶
|
AU2019410737A1
(en)
|
2018-12-21 |
2021-06-10 |
CureVac SE |
RNA for malaria vaccines
|
SG11202106666UA
(en)
|
2018-12-21 |
2021-07-29 |
Curevac Ag |
Methods for rna analysis
|
CN113474328A
(zh)
|
2019-01-11 |
2021-10-01 |
爱康泰生治疗公司 |
用于脂质纳米颗粒递送活性剂的脂质
|
JP2022518399A
(ja)
|
2019-01-14 |
2022-03-15 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合アンタゴニスト及びrnaワクチンを用いてがんを処置する方法
|
WO2020161342A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
US20200339638A1
(en)
|
2019-04-23 |
2020-10-29 |
Sangamo Therapeutics, Inc. |
Modulators of Chromosome 9 Open Reading Frame 72 Gene Expression and Uses Thereof
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
AU2020328855A1
(en)
|
2019-08-14 |
2022-03-03 |
CureVac SE |
RNA combinations and compositions with decreased immunostimulatory properties
|
AU2020407285A1
(en)
|
2019-12-20 |
2022-08-11 |
CureVac SE |
Lipid nanoparticles for delivery of nucleic acids
|
CA3164559A1
(en)
|
2020-01-31 |
2021-08-05 |
Lars Mueller |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
MX2022009460A
(es)
|
2020-02-04 |
2022-12-16 |
Curevac Ag |
Vacuna contra el coronavirus.
|
US11576966B2
(en)
|
2020-02-04 |
2023-02-14 |
CureVac SE |
Coronavirus vaccine
|
BR112022019781A2
(pt)
*
|
2020-04-22 |
2022-12-13 |
BioNTech SE |
Vacina para o coronavírus
|
AU2021279312A1
(en)
|
2020-05-29 |
2022-12-15 |
CureVac SE |
Nucleic acid based combination vaccines
|
US20230265454A1
(en)
|
2020-06-04 |
2023-08-24 |
BioNTech SE |
RNA Replicon for Versatile and Efficient Gene Expression
|
KR20230051172A
(ko)
|
2020-07-16 |
2023-04-17 |
아퀴타스 테라퓨틱스 인크. |
지질 나노 입자에 사용하기 위한 양이온성 지질
|
US20230272052A1
(en)
|
2020-07-31 |
2023-08-31 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
CN113234776A
(zh)
*
|
2020-08-20 |
2021-08-10 |
深圳市瑞吉生物科技有限公司 |
一种Cap2结构5`帽子类似物及其制备方法和应用
|
US20220064596A1
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
WO2022043551A2
(en)
|
2020-08-31 |
2022-03-03 |
Curevac Ag |
Multivalent nucleic acid based coronavirus vaccines
|
IL300997A
(en)
|
2020-09-08 |
2023-04-01 |
Genentech Inc |
Systems and methods for the production of pharmaceutical preparations using peristaltic pumps and restraints
|
MX2023006126A
(es)
|
2020-12-09 |
2023-07-28 |
BioNTech SE |
Produccion de arn.
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
EP4087938A2
(en)
|
2021-01-27 |
2022-11-16 |
CureVac AG |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
JP2024511206A
(ja)
|
2021-03-26 |
2024-03-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
EP4312988A2
(en)
|
2021-03-31 |
2024-02-07 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
AU2022271249A1
(en)
|
2021-05-04 |
2023-11-16 |
BioNTech SE |
Immunogen selection
|
IL309952A
(en)
|
2021-07-29 |
2024-03-01 |
BioNTech SE |
Compositions and methods for treating melanoma
|
CA3171750A1
(en)
|
2021-07-30 |
2023-02-02 |
Tim SONNTAG |
Mrnas for treatment or prophylaxis of liver diseases
|
AU2022336209A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
CA3230056A1
(en)
|
2021-09-03 |
2023-03-09 |
Patrick Baumhof |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
CN113957108A
(zh)
*
|
2021-09-09 |
2022-01-21 |
上海兆维科技发展有限公司 |
一种加帽rna的合成方法以及加帽rna转录反应液
|
WO2023066874A1
(en)
|
2021-10-18 |
2023-04-27 |
BioNTech SE |
Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
|
AU2022369342A1
(en)
|
2021-10-18 |
2024-03-14 |
BioNTech SE |
Modified replicable rna and related compositions and their use
|
WO2023138786A1
(en)
|
2022-01-21 |
2023-07-27 |
BioNTech SE |
Analysis of rna molecules using catalytic nucleic acids
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
US12037616B2
(en)
|
2022-03-01 |
2024-07-16 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
|
TW202403046A
(zh)
|
2022-03-21 |
2024-01-16 |
瑞士商Crispr治療公司 |
用於治療脂蛋白相關的疾病之方法及組成物
|
WO2023213378A1
(en)
|
2022-05-02 |
2023-11-09 |
BioNTech SE |
Replicon compositions and methods of using same for the treatment of diseases
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
WO2023237726A1
(en)
|
2022-06-10 |
2023-12-14 |
Pantarhei Oncology B.V. |
An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
|
US11878055B1
(en)
|
2022-06-26 |
2024-01-23 |
BioNTech SE |
Coronavirus vaccine
|
CN114941018B
(zh)
*
|
2022-06-28 |
2023-09-22 |
翌圣生物科技(上海)股份有限公司 |
cap1帽类似物的合成方法
|
WO2024017479A1
(en)
|
2022-07-21 |
2024-01-25 |
BioNTech SE |
Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
|
WO2024056856A1
(en)
|
2022-09-15 |
2024-03-21 |
BioNTech SE |
Systems and compositions comprising trans-amplifying rna vectors with mirna
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
DE202023106198U1
(de)
|
2022-10-28 |
2024-03-21 |
CureVac SE |
Impfstoff auf Nukleinsäurebasis
|
WO2024137589A2
(en)
|
2022-12-20 |
2024-06-27 |
Genentech, Inc. |
Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|